A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial. Novartis ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...

Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

UBS raised the firm’s price target on Amgen (AMGN) to $319 from $315 and keeps a Neutral rating on the shares. The firm is expecting an in-line ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Amgen (AMGN – Research Report), with a price target of $329.00. The company’s shares c ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling infla ...

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...